ALK and non-small cell lung carcinoma: The IMpower150 trial randomized chemotherapy-naive patients with advanced non-squamous NSCLC, including patients with EGFR or ALK genetic alterations who had disease progression or were intolerant to at least one line of therapy with an approved TKI (10% of the overall trial population), to one of three groups: atezolizumab/carboplatin/paclitaxel (ACP), carboplatin/paclitaxel/bevacizumab (BCP), or atezolizumab/carboplatin/paclitaxel/bevacizumab (ABCP).